See more : COSMOS Pharmaceutical Corporation (CSMYF) Income Statement Analysis – Financial Results
Complete financial analysis of LabGenomics Co., Ltd. (084650.KQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of LabGenomics Co., Ltd., a leading company in the industry within the sector.
You may be interested
- Green Battery Minerals Inc. (GEM.V) Income Statement Analysis – Financial Results
- Gogoro Inc. (GGROW) Income Statement Analysis – Financial Results
- Access Co., Ltd. (4813.T) Income Statement Analysis – Financial Results
- Zenith Steel Pipes & Industries Limited (ZENITHSTL.NS) Income Statement Analysis – Financial Results
- Tianyu Digital Technology (Dalian) Group Co., Ltd. (002354.SZ) Income Statement Analysis – Financial Results
LabGenomics Co., Ltd. (084650.KQ)
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 73.13B | 144.77B | 202.41B | 119.48B | 33.18B |
| Cost of Revenue | 40.73B | 48.01B | 77.00B | 47.73B | 20.23B |
| Gross Profit | 32.39B | 96.77B | 125.41B | 71.75B | 12.95B |
| Gross Profit Ratio | 44.30% | 66.84% | 61.96% | 60.05% | 39.03% |
| Research & Development | 2.81B | 1.86B | 556.87M | 0.00 | 0.00 |
| General & Administrative | 2.77B | 2.68B | 2.03B | 1.60B | 534.66M |
| Selling & Marketing | 10.37B | 6.66B | 4.71B | 4.29B | 2.03B |
| SG&A | 13.15B | 9.35B | 6.73B | 5.90B | 10.70B |
| Other Expenses | 23.23B | 326.92M | 394.81M | 169.23M | 0.00 |
| Operating Expenses | 39.19B | 30.56B | 20.89B | 16.84B | 11.75B |
| Cost & Expenses | 79.92B | 78.57B | 97.89B | 64.57B | 31.98B |
| Interest Income | 4.50B | 830.90M | 154.71M | 101.04M | 274.36M |
| Interest Expense | 4.97B | 573.97M | 208.03M | 223.80M | 415.79M |
| Depreciation & Amortization | 5.90B | 3.97B | 3.34B | 3.43B | 3.80B |
| EBITDA | -897.70M | 70.17B | 107.86B | 58.33B | 4.89B |
| EBITDA Ratio | -1.23% | 50.20% | 54.60% | 48.06% | 14.72% |
| Operating Income | -2.87B | 66.21B | 104.52B | 54.91B | 1.08B |
| Operating Income Ratio | -3.93% | 45.73% | 51.64% | 45.95% | 3.26% |
| Total Other Income/Expenses | -4.21B | -2.81B | 4.61B | -3.08B | -6.90M |
| Income Before Tax | -7.09B | 63.39B | 109.13B | 51.82B | 1.08B |
| Income Before Tax Ratio | -9.69% | 43.79% | 53.92% | 43.37% | 3.24% |
| Income Tax Expense | -1.84B | 15.47B | 25.28B | 9.06B | 112.86M |
| Net Income | -4.67B | 48.40B | 83.85B | 42.77B | 962.42M |
| Net Income Ratio | -6.39% | 33.43% | 41.43% | 35.79% | 2.90% |
| EPS | -63.22 | 714.50 | 413.50 | 649.33 | 15.50 |
| EPS Diluted | -63.22 | 714.50 | 413.50 | 649.33 | 15.50 |
| Weighted Avg Shares Out | 73.93M | 67.74M | 67.35M | 65.86M | 62.09M |
| Weighted Avg Shares Out (Dil) | 73.93M | 67.74M | 67.35M | 65.86M | 62.09M |
No news found for: 084650.KQ
Source: https://incomestatements.info
Category: Stock Reports